1 - 2 out of 2Page size: 10
  1. 2019

  2. Mesenchymal Neuroblastoma Cells Are Undetected by Current mRNA Marker Panels: The Development of a Specific Neuroblastoma Mesenchymal Minimal Residual Disease Panel

    van Wezel, E. M., van Zogchel, L. M. J., van Wijk, J., Timmerman, I., Vo, N-K., Zappeij-Kannegieter, L., deCarolis, B., Simon, T., van Noesel, M., Molenaar, J. J., van Groningen, T., Versteeg, R., Caron, H. N., van der Schoot, C. E., Koster, J., van Nes, J. & Tytgat, G., 3 Oct 2019, In: JCO Precision Oncology. 11 p.

    Research output: Contribution to journal › Article › Academic › peer-review

  3. Hypermethylated RASSF1A as Circulating Tumor DNA Marker for Disease Monitoring in Neuroblastoma

    van Zogchel, L. M. J., van Wezel, E. M., van Wijk, J., Stutterheim, J., Bruins, W. S. C., Zappeij-Kannegieter, L., Slager, T. J. E., Schumacher-Kuckelkorn, R., Verly, I. R. N., van der Schoot, C. E. & Tytgat, G. A. M., 2019, In: JCO Precision Oncology. 3, p. 291-306 16 p.

    Research output: Contribution to journal › Article › Academic › peer-review

ID: 110900